Literature DB >> 23595944

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.

Bianca Weinstock-Guttman1, Robert Zivadinov, Dana Horakova, Eva Havrdova, Jun Qu, Grace Shyh, Elizabeth Lakota, Kerri O'Connor, Darlene Badgett, Miriam Tamaño-Blanco, Michaela Tyblova, Sara Hussein, Niels Bergsland, Laura Willis, Jan Krasensky, Manuela Vaneckova, Zdenek Seidl, Murali Ramanathan.   

Abstract

OBJECTIVES: To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.
METHODS: High density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were obtained in pretreatment serum from 135 high risk patients with CIS (≥ 2 brain MRI lesions and ≥ 2 oligoclonal bands) enrolled in the Observational Study of Early Interferon β-1a Treatment in High Risk Subjects after CIS study (SET study), which prospectively evaluated the effect of intramuscular interferon β-1a treatment following the first demyelinating event. Thyroid stimulating hormone, free thyroxine, 25-hydroxy vitamin D3, active smoking status and body mass index were also obtained. Clinical and MRI assessments were obtained within 4 months of the initial demyelinating event and at 6, 12 and 24 months.
RESULTS: The time to first relapse and number of relapses were not associated with any of the lipid profile variables. Higher LDL-C (p=0.006) and TC (p=0.001) levels were associated with increased cumulative number of new T2 lesions over 2 years. Higher free thyroxine levels were associated with lower cumulative number of contrast-enhancing lesions (p=0.008). Higher TC was associated as a trend with lower baseline whole brain volume (p=0.020). Higher high density lipoprotein was associated with higher deseasonalised 1,25-dihydroxy vitamin D3 (p=0.003) levels and a trend was found for deseasonalised 25-hydroxy vitamin D3 (p=0.014).
CONCLUSIONS: In early multiple sclerosis, lipid profile variables particularly LDL-C and TC levels are associated with inflammatory MRI activity measures.

Entities:  

Keywords:  Clinical Neurology; Mri; Multiple Sclerosis; Neurobiology; Neuroradiology

Mesh:

Substances:

Year:  2013        PMID: 23595944     DOI: 10.1136/jnnp-2012-304740

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  45 in total

1.  Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Authors:  Kelly Fellows; Tomas Uher; Richard W Browne; Bianca Weinstock-Guttman; Dana Horakova; Helena Posova; Manuela Vaneckova; Zdenek Seidl; Jan Krasensky; Michaela Tyblova; Eva Havrdova; Robert Zivadinov; Murali Ramanathan
Journal:  J Lipid Res       Date:  2015-08-04       Impact factor: 5.922

2.  Comorbidity increases the risk of hospitalizations in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-12-24       Impact factor: 9.910

Review 3.  Dietary Interventions and Multiple Sclerosis.

Authors:  Ghadah Altowaijri; Allison Fryman; Vijayshree Yadav
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

Review 4.  Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.

Authors:  Rachel Brandstadter; Ilana Katz Sand; James F Sumowski
Journal:  Mult Scler       Date:  2019-09       Impact factor: 6.312

5.  Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Authors:  Tomas Uher; Kelly Fellows; Dana Horakova; Robert Zivadinov; Manuela Vaneckova; Lukas Sobisek; Michaela Tyblova; Zdenek Seidl; Jan Krasensky; Niels Bergsland; Bianca Weinstock-Guttman; Eva Havrdova; Murali Ramanathan
Journal:  J Lipid Res       Date:  2016-12-06       Impact factor: 5.922

6.  Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

Authors:  Shreya Mukhopadhyay; Kelly Fellows; Richard W Browne; Prachi Khare; Sandhya Krishnan Radhakrishnan; Jesper Hagemeier; Bianca Weinstock-Guttman; Robert Zivadinov; Murali Ramanathan
Journal:  Mult Scler       Date:  2016-09-28       Impact factor: 6.312

Review 7.  Wellness and the Role of Comorbidities in Multiple Sclerosis.

Authors:  Brandon P Moss; Mary R Rensel; Carrie M Hersh
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

8.  Cardiovascular profile improvement during Natalizumab treatment.

Authors:  Marcello Moccia; Roberto Albero; Roberta Lanzillo; Francesco Saccà; Anna De Rosa; Cinzia Valeria Russo; Antonio Carotenuto; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Metab Brain Dis       Date:  2017-12-18       Impact factor: 3.584

9.  Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis.

Authors:  R Zivadinov; B Raj; M Ramanathan; B Teter; J Durfee; M G Dwyer; N Bergsland; C Kolb; D Hojnacki; R H Benedict; B Weinstock-Guttman
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-18       Impact factor: 3.825

Review 10.  The Evidence for Dietary Interventions and Nutritional Supplements as Treatment Options in Multiple Sclerosis: a Review.

Authors:  Leah J Mische; Ellen M Mowry
Journal:  Curr Treat Options Neurol       Date:  2018-03-17       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.